GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Decision Diagnostics Corp (OTCPK:DECN) » Definitions » Net Current Asset Value

Decision Diagnostics (Decision Diagnostics) Net Current Asset Value : $-0.01 (As of Sep. 2021)


View and export this data going back to . Start your Free Trial

What is Decision Diagnostics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Decision Diagnostics's net current asset value per share for the quarter that ended in Sep. 2021 was $-0.01.

The historical rank and industry rank for Decision Diagnostics's Net Current Asset Value or its related term are showing as below:

DECN's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 6.725
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Decision Diagnostics Net Current Asset Value Historical Data

The historical data trend for Decision Diagnostics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Decision Diagnostics Net Current Asset Value Chart

Decision Diagnostics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec17 Dec18 Dec19 Dec20
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 -0.01 -0.01 -0.02 -0.01

Decision Diagnostics Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of Decision Diagnostics's Net Current Asset Value

For the Pharmaceutical Retailers subindustry, Decision Diagnostics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Decision Diagnostics's Price-to-Net-Current-Asset-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Decision Diagnostics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Decision Diagnostics's Price-to-Net-Current-Asset-Value falls into.



Decision Diagnostics Net Current Asset Value Calculation

Decision Diagnostics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2020 is calculated as

Net Current Asset Value Per Share(A: Dec. 2020 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.627-5.17-0-0.001)/356.431
=-0.01

Decision Diagnostics's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2021 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2021 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.274-5.395-0-0.001)/357.871
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Decision Diagnostics  (OTCPK:DECN) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Decision Diagnostics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Decision Diagnostics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Decision Diagnostics (Decision Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
2660 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Decision Diagnostics Corp is a provider of prescription drugs, home testing products for the chronically ill, direct to patient diabetes programs, and a developer of revolutionary, cell phone centric, e-health products and technology. The company also provides blood glucose home testing test strips and exciting new concepts for blood testing monitors.
Executives
Keith Berman director, officer: Secretary 2660 TOWNSGATE RD #300, WESTLAKE VILLAGE CA 91361
Robert Jagunich director 765 CHRISTINE DR PALO ALTO CA 94303
Robert Lawrence Cox director, officer: President

Decision Diagnostics (Decision Diagnostics) Headlines

From GuruFocus